Legend Biotech Corp ADR (LEGN) Stock Price, Quote & News

Company Profile

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candida...

Industry: Biotechnology

Sector: Healthcare

Phone: 737 317 5050

Website: legendbiotech.com

Address:

2101 Cottontail Lane, Somerset, United States

KY3000 Jul. 2 at 8:01 PM

$LEGN this is primed, I don’t know when

0 · Reply

KY3000 Jul. 2 at 3:42 PM

$LEGN 40

0 · Reply

KY3000 Jul. 1 at 7:35 PM

$LEGN LFG

0 · Reply

BioRich Jul. 1 at 4:40 PM

$CAPR Stocktwits Q2 Quarterly Filing: @BioRich Top 50 portfolio positions: 1) GUTS 2) ABVX 3) IBRX 4) ALT 5) KYTX 6) DAVE 7) CADL 8) MIST 9) UEC 10) OTLK 11) CAPR 12) $TGTX 13) $SABS 14) $NVAX 15) $LEGN 16) VKTX 17) OCUL 18) SOFI 19) BBIO 20) SGP 21) VNDA 22) SHAZ 23) NRXP 24) GPCR 25) EWTX 26) TLSA 27) SKM 28) MLTX 29) SNDX 30) JMIA 31) NKTR 32) VVOS 33) RGNX 35) ARRNF 36) CRMD 37) WVE 38) NUVB 39) SMMT 40) ANNX 41) CGON 42) TEM 43) IVA 44) PSN 45) LGND 46) IMVT 47) MPLT 48)NNE 49) ARDX 50) COGT If I own it, I believe in it. What am I missing? Hold too much? Not enough? Look forward to your feedback! Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

9 · Reply

kiwiSurfer Jul. 1 at 3:11 PM

$LEGN In mid-2026, First Beijing Investment Ltd (a concentrated fund focused on Chinese tech and consumer sectors) disclosed a new position in LEGN of approximately 2.3 million shares. Xi owns no shares personally.

1 · Reply

KY3000 Jul. 1 at 11:48 AM

$LEGN Xi has+- 3 million shares. I don’t think anything less than300$ mill with CRVs is what he will approve

0 · Reply

KY3000 Jul. 1 at 8:54 AM

$LEGN after the ER we will see. Ppl want to see 5$ bill projected carvaki sales on track, with 5$ bill market cap. I don’t think BO price figured out yet, but 40$-50 a share is a no go

0 · Reply

Biotechsamy Jun. 30 at 9:05 PM

$LEGN are you guys watching abivax drama? CEO admitted this morning that raising funds gives him more optionality in M&A discussions. Now there is a public offering to raise $600M this afterhour.

1 · Reply

Biotechsamy Jun. 29 at 10:04 PM

$LEGN JnJ chief of R&D John Reed on how they approach M&A: “wait for the technology to get sufficiently de-risked that we could pounce”. In a few months, $LEGN will be ripe to get pounced on.

1 · Reply

SmartAlphaa Jun. 29 at 9:09 PM

$LEGN hanging out around 29 after digesting that recent equity raise. The LB2501 clinical data is a major talking point. Analysts are still constructive with price targets up to 49. Needs to hold this support level.

0 · Reply

Legend Biotech falls -14.4%

2026-06-18T14:07:36.000Z - 16 days ago

Legend Biotech falls -12.2%

2026-06-18T02:05:06.000Z - 16 days ago

Legend Biotech 7.7M share Spot Secondary priced at $29.35

Jun 17, 2026, 9:21 PM EDT - 16 days ago

Legend Biotech Corporation Announces Pricing of Public Offering

2026-06-17T21:10:10.000Z - 16 days ago

Legend Biotech secondary offering; price range $29.35-$31.35

2026-06-17T20:36:48.000Z - 16 days ago

Legend Biotech announces $225M offering of American Depositary Shares

Jun 17, 2026, 4:29 PM EDT - 16 days ago

Legend Biotech Corporation Announces Proposed Public Offering

2026-06-16T18:45:37.000Z - 17 days ago

Legend Biotech management to meet with Oppenehimer

2026-06-15T12:13:53.000Z - 19 days ago

Legend Biotech announces clinical proof-of-concept data for LB2501

$Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma$

Jun 15, 2026, 8:00 AM EDT - 19 days ago

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

2026-06-14T20:50:52.000Z - 19 days ago

Legend Biotech announces first clinical proof-of-concept data for LB2501

2026-06-03T11:33:22.000Z - 4 weeks ago

Legend Biotech price target raised to $49 from $31 at UBS

2026-06-03T10:16:18.000Z - 4 weeks ago

Legend Biotech price target raised to $65 from $50 at H.C. Wainwright

2026-06-02T17:21:37.000Z - 4 weeks ago

This Is Why Legend Biotech Stock (LEGN) Was Up Today

2026-06-02T16:18:47.000Z - 4 weeks ago

Legend Biotech rises 29.5%

2026-06-02T14:06:38.000Z - 4 weeks ago

Legend Biotech presents preliminary clinical data for LB2501 at EHA Congress

Jun 2, 2026, 9:31 AM EDT - 4 weeks ago

Legend's experimental cell therapy shows promise in blood cancer patients

Jun 2, 2026, 9:30 AM EDT - 4 weeks ago

Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)

2026-06-01T16:05:07.000Z - 4 weeks ago

Legend Biotech presents first-in-human LB2102 results in solid tumors

Jun 1, 2026, 10:00 AM EDT - 4 weeks ago

Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026

May 31, 2026, 7:00 PM EDT - 4 weeks ago

Legend Biotech Transcript: American Society of Clinical Oncology (ASCO) Annual Meeting 2026

May 21, 2026, 5:00 PM EDT - 6 weeks ago

Legend Biotech Announces Presentations at ASCO 2026

2026-05-13T16:55:07.000Z - 7 weeks ago

Legend Biotech price target lowered to $48 from $49 at Morgan Stanley

2026-05-13T15:57:12.000Z - 7 weeks ago

Legend Biotech price target raised to $29 from $21 at TD Cowen

2026-05-13T15:00:09.000Z - 7 weeks ago

Legend Biotech price target raised to $64 from $62 at RBC Capital

May 12, 2026, 8:00 AM EDT - 7 weeks ago

Legend Biotech Earnings Call Transcript: Q1 2026

May 12, 2026, 8:00 AM EDT - 7 weeks ago

Legend Biotech Earnings release: Q1 2026

May 12, 2026, 8:00 AM EDT - 7 weeks ago

Legend Biotech Slides: Q1 2026

May 12, 2026, 7:00 AM EDT - 7 weeks ago

Legend Biotech Reports First Quarter 2026 Results and Recent Highlights

May 4, 2026, 8:00 AM EDT - 2 months ago

Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results

Mar 10, 2026, 8:00 AM EDT - 4 months ago

Legend Biotech Earnings Call Transcript: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 4 months ago

Legend Biotech Annual report: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 4 months ago

Legend Biotech Earnings release: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 4 months ago

Legend Biotech Slides: Q4 2025

Mar 10, 2026, 7:00 AM EDT - 4 months ago

Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

Feb 24, 2026, 8:00 AM EST - 4 months ago

Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results

Jan 14, 2026, 12:00 PM EST - 6 months ago

Legend Biotech Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 12:00 PM EST - 6 months ago

Legend Biotech Slides: 44th Annual J.P. Morgan Healthcare Conference

Dec 9, 2025, 3:31 PM EST - 7 months ago

Cancer Study Buoys These Small Biotechs

ACLX TERN

Dec 6, 2025, 2:00 PM EST - 7 months ago

Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025

Dec 3, 2025, 7:00 AM EST - 7 months ago

Legend Biotech Slides: Corporate presentation

Nov 13, 2025, 12:08 PM EST - 8 months ago

Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

Nov 12, 2025, 8:00 AM EST - 8 months ago

Legend Biotech Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:00 AM EST - 8 months ago

Legend Biotech Earnings release: Q3 2025

Nov 12, 2025, 8:00 AM EST - 8 months ago

Legend Biotech Slides: Q3 2025

Nov 3, 2025, 11:05 AM EST - 8 months ago

Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Oct 29, 2025, 8:00 AM EDT - 8 months ago

Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results

Oct 10, 2025, 6:36 PM EDT - 9 months ago

US FDA adds boxed warning to J&J, Legend Biotech's cancer therapy

JNJ

Sep 9, 2025, 4:05 PM EDT - 10 months ago

Legend Biotech Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 7:00 AM EDT - 10 months ago

Legend Biotech Slides: Corporate Presentation

Aug 18, 2025, 8:00 AM EDT - 11 months ago

Legend Biotech Appoints Carlos Santos as Chief Financial Officer

Aug 11, 2025, 8:00 AM EDT - 11 months ago

Legend Biotech Earnings Call Transcript: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 11 months ago

Legend Biotech Earnings release: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 11 months ago

Legend Biotech Slides: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 11 months ago

Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights

Jul 1, 2025, 10:00 AM EDT - 1 year ago

Legend Biotech Slides: Corporate Presentation

Jun 4, 2025, 6:10 PM EDT - 1 year ago

Mizuho's Jared Holz details potential biotech, pharma acquisitions

INSM VRNA

Jun 3, 2025, 10:45 AM EDT - 1 year ago

Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting

May 22, 2025, 5:15 PM EDT - 1 year ago

Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT

May 13, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Earnings Call Transcript: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Earnings release: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Slides: Q1 2025

May 13, 2025, 7:00 AM EDT - 1 year ago

Legend Biotech Reports First Quarter 2025 Results and Recent Highlights

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Earnings Call Transcript: Q4 2024

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Annual report: Q4 2024

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Earnings release: Q4 2024

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Slides: Q4 2024

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights

Jan 14, 2025, 6:45 PM EST - 1 year ago

Legend Biotech Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 6:45 PM EST - 1 year ago

Legend Biotech Slides: FY 2025

Dec 19, 2024, 8:01 AM EST - 1 year ago

Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference

$CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma$

Dec 9, 2024, 7:35 PM EST - 1 year ago

CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma

Dec 8, 2024, 11:00 PM EST - 1 year ago

Legend Biotech Transcript: The 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Legend Biotech Earnings Call Transcript: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Legend Biotech Earnings release: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Legend Biotech Slides: Q3 2024

Nov 7, 2024, 7:30 AM EST - 1 year ago

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Nov 5, 2024, 9:10 AM EST - 1 year ago

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

Nov 4, 2024, 7:30 AM EST - 1 year ago

Legend Biotech Appoints Alan Bash as President of CARVYKTI®

Oct 3, 2024, 7:41 AM EDT - 1 year ago

Legend Biotech to set up new R&D facility in Philadelphia

Oct 3, 2024, 7:30 AM EDT - 1 year ago

Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

Sep 27, 2024, 4:35 PM EDT - 1 year ago

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

Sep 24, 2024, 9:00 AM EDT - 1 year ago

Multiply Labs Announces a Collaboration on Automating Cell Therapy Manufacturing with Legend Biotech

Sep 4, 2024, 2:35 PM EDT - 1 year ago

Legend Biotech Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 20, 2024, 8:00 AM EDT - 2 years ago

Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 9, 2024, 8:00 AM EDT - 2 years ago

Legend Biotech Earnings Call Transcript: Q2 2024

Aug 9, 2024, 8:00 AM EDT - 2 years ago

Legend Biotech Earnings release: Q2 2024

Aug 9, 2024, 8:00 AM EDT - 2 years ago

Legend Biotech Slides: Q2 2024

Aug 9, 2024, 7:00 AM EDT - 2 years ago

Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights

Jul 26, 2024, 7:00 AM EDT - 2 years ago

Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024

Jul 10, 2024, 8:00 AM EDT - 2 years ago

Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results

Jun 6, 2024, 10:30 AM EDT - 2 years ago

Legend Biotech Transcript: Jefferies 2024 Global Healthcare Conference

Jun 3, 2024, 4:00 PM EDT - 2 years ago

Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA

KY3000 Jul. 2 at 8:01 PM

$LEGN this is primed, I don’t know when

0 · Reply

KY3000 Jul. 2 at 3:42 PM

$LEGN 40

0 · Reply

KY3000 Jul. 1 at 7:35 PM

$LEGN LFG

0 · Reply

BioRich Jul. 1 at 4:40 PM

9 · Reply

kiwiSurfer Jul. 1 at 3:11 PM

1 · Reply

KY3000 Jul. 1 at 11:48 AM

$LEGN Xi has+- 3 million shares. I don’t think anything less than300$ mill with CRVs is what he will approve

0 · Reply

KY3000 Jul. 1 at 8:54 AM

$LEGN after the ER we will see. Ppl want to see 5$ bill projected carvaki sales on track, with 5$ bill market cap. I don’t think BO price figured out yet, but 40$-50 a share is a no go

0 · Reply

Biotechsamy Jun. 30 at 9:05 PM

$LEGN are you guys watching abivax drama? CEO admitted this morning that raising funds gives him more optionality in M&A discussions. Now there is a public offering to raise $600M this afterhour.

1 · Reply

Biotechsamy Jun. 29 at 10:04 PM

$LEGN JnJ chief of R&D John Reed on how they approach M&A: “wait for the technology to get sufficiently de-risked that we could pounce”. In a few months, $LEGN will be ripe to get pounced on.

1 · Reply

SmartAlphaa Jun. 29 at 9:09 PM

0 · Reply

JuggernautRaider Jun. 29 at 10:55 AM

$SLS $ALT $TNXP spread the word @BioRich sadly does not know what he is doing. These three have been hidden gems in plain sight 💎 💎 💎 💎 SLS may be peaking out soon. But ALT, IMRX, and TNXP could each 3-10x quickly 🤫 GHCA - Global Health Care Academy 🏫 Will be open soon. We will expose fraudsters of all time, sharing incredible stocks to buy, and i will share my favorite targets to short. $LEGN may be my top short selling target the next 6 months. 😈 China and Europe are robbing the US pharmaceutical sector BLIND! Where is @PresidentTrump2025 when we need him?

5 · Reply

cklee88 Jun. 29 at 4:11 AM

$LEGN simple mathematic, conservative carvykti sales of 1.5b and np of 150b, PE 20 means 3 billion, valuation for LB2501, LB2503 and LB2505 of 1b each, total = 6b..so now is not expensive

0 · Reply

kiwiSurfer Jun. 27 at 9:54 PM

$LEGN I feel the odds of LEGN getting bought are about 80% be November data drop the data is too promising plus BOD moves by LEGN and restructuring by JNJ mean the stars are aligned.

0 · Reply

Stockseeking Jun. 27 at 3:09 AM

$LEGN No sale below 43, we will see in the coming months

1 · Reply

KY3000 Jun. 26 at 10:57 PM

$LEGN JJ selling orthopedics unit, pretty strange after said yesterday mRNA coming to clinic with their own invivo car t. I think it’s starting to bubble

1 · Reply

DiamondHandsBTW Jun. 26 at 5:51 PM

$LEGN this stock blows

0 · Reply

Olena Jun. 26 at 4:58 PM

$LEGN did offering close yet? what's the money for? I thought they are profitable now

0 · Reply

Biotech80 Jun. 25 at 1:07 PM

$SOUN wouldn’t worry about them only 3 months ago was in $LEGN at $17.02 they was sell sell sell I was buy buy buy l sold at $30.87 same as this now

1 · Reply

WolfofWallasey Jun. 25 at 12:35 PM

$LUNR hmmm if this gets to $17 or even below $18 I thinks it’s a heck of deal for a swing up Such a good company Just pains me as I’d need to sell some $LEGN or $RXRX Tough decision but I do love LUNR and this feels like an entry opportunity when it finds its bottom

2 · Reply

Biotechsamy Jun. 25 at 1:15 AM

$LEGN nothing new, just additional info on underwriters https://www.wsgr.com/en/insights/firm-advises-underwriters-on-legend-biotechs-public-offering.html#:~:text=In%20addition%2C%20Legend%20Biotech%20has%20granted%20the,the%20underwriters'%20option%20to%20purchase%20additional%20ADSs.

0 · Reply

Biotechsamy Jun. 24 at 8:24 PM

$LEGN FWIW

0 · Reply

CloudMatt Jun. 24 at 2:42 PM

$LEGN Probably a good time to buy now. Glad I got the chance to get some more.

0 · Reply

Market Cap	5.56B
Revenue (ttm)	1.03B
Net Income (ttm)	-296.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	10,461.50
Profit Margin	-28.85%
Debt to Equity Ratio	0.27

Volume	1,407,000
Avg Vol	2,768,716
Day's Range	N/A - N/A
Shares Out	185.74M
Stochastic %K	83%
Beta	0.34
Analysts	Strong Sell
Price Target	$57.53